Modality
Radioligand
MOA
BiTE
Target
ALK
Pathway
Sphingolipid
Pancreatic Ca
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
Nov 2018
→ Jun 2031
Phase 2Current
NCT05939815
2,825 pts·Pancreatic Ca
2018-11→2029-07·Not yet recruiting
NCT05167397
2,338 pts·Pancreatic Ca
2022-09→2031-06·Recruiting
5,163 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-07-153.3y awayPh3 Readout· Pancreatic Ca
2031-06-245.2y awayPh3 Readout· Pancreatic Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Not yet…
P2/3
Recruit…
Catalysts
Ph3 Readout
2029-07-15 · 3.3y away
Pancreatic Ca
Ph3 Readout
2031-06-24 · 5.2y away
Pancreatic Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05939815 | Phase 2/3 | Pancreatic Ca | Not yet recr... | 2825 | EFS |
| NCT05167397 | Phase 2/3 | Pancreatic Ca | Recruiting | 2338 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BII-8315 | Biogen | NDA/BLA | CDK2 |